XBiotech lines up for a $76M IPO to fund its antibody R&D

Austin, TX's XBiotech has filed to make a $76 million Wall Street debut, plotting to bankroll a fleet of antibody therapies and an ambitious plan for a manufacturing and R&D campus. The company expects to offer 4 million shares at between $18 and $20 each, earmarking the majority of its proceeds to pay for Phase III trials on Xilonix, an interleukin-1 blocker with applications in multiple cancers. XBiotech plans to set aside $12 million of its haul to fund construction on a 46,000-square-foot operation in Austin, to which it is adding a commercial manufacturing facility. More

Suggested Articles

Acceleron has chalked up another phase 2 flop as its pipeline thins a little more.

Seven years after regaining the fibrosis drug it had licensed out to Stromedix, Biogen is pulling the plug on a phase 2 study.

Smaller biotechs are continuing their biopharma hiring spree as two startups nab some big names for their aspiring cancer drug research.